KTX-0141
Selective TrkB PAM neuroplastogen for major depressive disorder
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
KTX-0141 is Kasvu Therapeutics' lead small-molecule TrkB positive allosteric modulator candidate. Public materials describe robust neuroplasticity signals and CNS penetration in preclinical work without hallucinogenic activity in standard models, with IND/CTA-enabling studies underway and clinical development planned for the second half of 2027 in major depressive disorder.
- Website
- kasvutx.com
- Added via
- web
- Ownership
- unclaimed
Where to go
Product details
- Product kind
- Other